Sequential Treatment of Hepatocellular Carcinoma by Transarterial Chemoembolization and Local Ablation or External Radiation

Completed

• Conditions: Hepatocellular Carcinoma

• Registration Number: NCT04813861
• Lead Sponsor: Central Hospital, Nancy, France

Brief Summary

Hepatocellular carcinoma (HCC) can present itself in many forms (size, number of lesions) for the treatment of which a therapeutic panel can be elaborated and layered. If a curative treatment cannot be considered in case of an HCC classified in an intermediate stage, a Transcatheter Arterial Chemoembolization (TACE) can be proposed. In case of a partial response or the treatment of some lesions of a multifocal HCC, a combined treatment by stereotaxic radiotherapy (CK), radiofrequency ablation (RFA) or microwave ablation (MWA) may be initiated in accordance with a decision of the multidisciplinary consultation meeting.

The aim of this study was to evaluate the clinical outcome of HCC receiving MWA, RFA or CK after downstaging with TACE.

Detailed Description

Not available

Study Timeline

• Study Start: 2010-01-04
• Primary Completion: 2019-12
• Status Verified: 2021-03
• Study Completion: 2021-03
• Study First Submitted: 2021-03-21
• Study First Submitted QC: 2021-03-21
• Last Update Submitted: 2021-03-21
• Study First Posted: 2021-03-24
• Last Update Posted: 2021-03-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 57

Inclusion Criteria

• a HCC treated by TACE followed by RFA, MWA and/or CK
• from 01/2010 to 12/2020
• treated by Nancy Regional University Hospital (TACE, RFA, MWA) and Institut de Cancérologie de Lorraine (CK)

Exclusion Criteria

• Combined treatment over one year following the last TACE
• No baseline, in between or after combined treatment imaging
• Lesion appeared after TACE treatment

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Lesion Response	4-6 weeks after BWA or RFA or 3-6 months after CK	Lesion response after combined treatment

Secondary Outcome Measures

Name	Time	Method
Delayed Lesion Response	1 year after BWA, RFA or CK	Lesion response a year after combined treatment

Trial Locations

Locations (1)

CHRU de Nancy; 🇫🇷 Nancy, France